STOCK TITAN

HYPERFINE - HYPR STOCK NEWS

Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.

About Hyperfine, Inc. (Nasdaq: HYPR)

Hyperfine, Inc. is a pioneering medical device company dedicated to transforming the landscape of diagnostic imaging through innovation and accessibility. The company has developed the Swoop® Portable MR Imaging System, the first FDA-cleared, portable, ultra-low-field magnetic resonance imaging (MRI) system. Designed to address the limitations of traditional MRI technology, the Swoop® system provides a cost-effective, portable, and user-friendly solution that brings imaging directly to the patient's bedside. This groundbreaking technology is particularly valuable in critical care settings such as neurointensive care units, emergency departments, and pediatric wards, where immediate access to diagnostic imaging can significantly impact clinical decision-making.

Core Business Model

Hyperfine generates revenue through two primary channels: device sales and subscription-based services. Device sales encompass the purchase of the Swoop® system, while subscription services include bundled offerings such as software updates, maintenance, and technical support. This dual revenue model ensures a steady income stream while encouraging long-term customer relationships. The Swoop® system's affordability—costing less than the annual service contract for many conventional MRI systems—further enhances its appeal to healthcare providers operating within budget constraints.

Innovative Technology and Clinical Relevance

The Swoop® Portable MR Imaging System is a technological breakthrough in the medical imaging industry. Unlike traditional MRI systems that require specialized facilities and high operational costs, the Swoop® system is portable, easy to operate, and can be powered by a standard electrical outlet. Controlled via an Apple iPad®, the system delivers high-quality images within minutes, enabling timely and informed clinical decisions. Its ultra-low-field imaging technology is designed to complement, rather than replace, stationary MRI systems, offering a flexible and scalable solution for diverse clinical environments.

Market Position and Competitive Landscape

Hyperfine operates within the highly competitive medical imaging market, which includes established players offering traditional MRI systems. However, the company differentiates itself through its focus on portability, accessibility, and cost-efficiency. By addressing the logistical and financial barriers associated with conventional MRI technology, Hyperfine is uniquely positioned to serve underserved markets, including rural healthcare facilities and resource-limited settings. The Swoop® system's ease of use—requiring less than 30 minutes of training—further enhances its adoption potential among clinicians and healthcare providers.

Global Reach and Regulatory Approvals

Hyperfine has achieved significant milestones in regulatory approvals, with the Swoop® system receiving FDA clearance in the United States, as well as certifications in Canada, Australia, the United Kingdom, the European Union, and New Zealand. These approvals underscore the system's clinical validity and open pathways for international market expansion, enabling Hyperfine to address a global need for accessible diagnostic imaging.

Significance in the Healthcare Industry

The Swoop® system represents a paradigm shift in diagnostic imaging, making MRI technology accessible to a broader range of patients and healthcare providers. Its portability and affordability are particularly impactful in emergency and critical care settings, where timely imaging can be life-saving. By complementing traditional MRI systems, Hyperfine is redefining the neuroimaging workflow, enhancing efficiency, and improving patient outcomes.

Conclusion

Hyperfine, Inc. is at the forefront of innovation in medical imaging, addressing critical gaps in accessibility and cost-effectiveness. Through its Swoop® Portable MR Imaging System, the company is not only transforming the way diagnostic imaging is delivered but also setting new standards for portability, ease of use, and clinical relevance. As a disruptive force in the healthcare industry, Hyperfine continues to make strides in democratizing medical imaging, bringing life-saving technology to patients anytime, anywhere.

Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announces participation in the Piper Sandler 35th Annual Healthcare Conference in New York. The company will present its groundbreaking FDA-cleared portable MRI brain imaging system, the Swoop® system, on November 30, 2023, at 9:30 am PT. A live webcast and archived recording will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
conferences
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announced third quarter 2023 financial results, with revenues of $2.33 million, six commercial Swoop® systems sold, and a net loss of $10.76 million. The company also provided a business update, including FDA clearance for new AI-powered software and progress in clinical programs such as an upcoming Alzheimer's feasibility study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.37%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. announced initial findings from a multicenter study on the use of portable MR brain imaging in assessing acute brain injury in ECMO patients. The study demonstrated the feasibility of using portable MR brain imaging for monitoring patients during ECMO use and highlighted its potential advantage in providing early visualization of ischemic stroke compared to CT scans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
none
Rhea-AI Summary
Hyperfine, Inc. to report financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
-
Rhea-AI Summary
Hyperfine, Inc. promotes Dr. Edmond Knopp and Dr. Chip Truwit as vice presidents of medical affairs and scientific affairs respectively, highlighting their expertise in radiology and neuroradiology. Dr. Knopp will focus on advancing brain health in stroke care and Alzheimer's therapies, while Dr. Truwit will lead clinical innovation projects. These appointments demonstrate Hyperfine's commitment to developing ultra-low-field MR brain imaging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
management
-
Rhea-AI Summary
Hyperfine, Inc. announces FDA clearance of updated software for their Swoop® ultra-low-field brain imaging system, incorporating advanced AI algorithms for image quality enhancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
Rhea-AI Summary
Hyperfine, Inc. to present at Gilmartin Group Emerging Growth Showcase on September 21, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
conferences acquisition
-
Rhea-AI Summary
Hyperfine, Inc. reports Q2 2023 revenue of $3.38M, up from $1.53M in Q2 2022. Net loss for Q2 2023 is $10.64M, compared to $23.16M in Q2 2022. Full-year 2023 revenue expected to be $10-14M. Cash burn for 2023 expected to be $40-45M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.45%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags

FAQ

What is the current stock price of HYPERFINE (HYPR)?

The current stock price of HYPERFINE (HYPR) is $0.93 as of March 3, 2025.

What is the market cap of HYPERFINE (HYPR)?

The market cap of HYPERFINE (HYPR) is approximately 78.2M.

What is Hyperfine, Inc. known for?

Hyperfine, Inc. is known for developing the Swoop® Portable MR Imaging System, the first portable, FDA-cleared MRI system for bedside imaging.

How does Hyperfine generate revenue?

Hyperfine generates revenue through device sales and subscription-based services for software, maintenance, and technical support.

What makes the Swoop® system unique?

The Swoop® system is portable, cost-effective, and easy to use, providing high-quality imaging directly at the patient’s bedside within minutes.

Who are Hyperfine's target customers?

Hyperfine targets healthcare providers in critical care settings, including neurointensive care units, emergency departments, and pediatric wards.

What are the regulatory approvals for the Swoop® system?

The Swoop® system has received FDA clearance in the U.S. and certifications in Canada, Australia, the UK, the EU, and New Zealand.

How does the Swoop® system complement traditional MRI systems?

The Swoop® system complements traditional MRI systems by offering a portable, accessible solution for immediate bedside imaging when stationary systems are impractical.

What challenges does Hyperfine face in the market?

Hyperfine faces challenges such as market adoption, competition from established imaging companies, and the need to continually improve image quality and clinical applicability.

How long does it take to train new users on the Swoop® system?

Training new users on the Swoop® system takes less than 30 minutes, making it highly accessible for clinicians.
HYPERFINE

Nasdaq:HYPR

HYPR Rankings

HYPR Stock Data

78.23M
56.94M
9.5%
24.35%
2.14%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
GUILFORD